New hope for mechanism-based treatment of Parkinson's disease

Drug Discovery Today

Volumn 10, Issue 2, 2005, Pages 80-81

  Bradbury, Jane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BAICALEIN; DOXYCYCLINE; FLAVONOID; RIFAMPICIN;

DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; NOTE; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION;

EID: 13844281010     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03340-9     Document Type: Short Survey

References (3)

1. Li J., et al. Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11:2004;1513-1521
2. Zhu M., et al. The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J. Biol. Chem. 25:2004;26846-26857
3. Loeb M.B., et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatr. Soc. 52:2004;381-387